STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY
|
|
- Jasmin Holland
- 6 years ago
- Views:
Transcription
1 STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY
2 State of the Asia-Pacific Pharmaceutical Industry The pharmaceutical industry in the Asia-Pacific region has recently been besieged by a number of high-profile challenges affecting public confidence and challenging the industry s ability to remain competitive in the global marketplace. Leading multinational pharmaceutical companies have been singled out regarding the ethics of their business practices. These criticisms have been preceded by longstanding concerns in the region about the cost of and access to medicines (and health care, generally), including, but not limited to, practices related to physician engagement, affordable pricing and non-communicable disease (NCD) management. Nonetheless, foreign multinational pharmaceutical companies continue to look to the Asia-Pacific region for growth and development, as demonstrated by recent investments in research and development, as well as the manufacturing of products. However, this convergence of issues and opportunities poses critical questions about how the industry should respond to ever-increasing demands from stakeholders to remain trusted and responsible now and in the future. APCO Worldwide and its research consultancy, APCO Insight, developed the Return on Reputation (ROR) Indicator to better understand and address key stakeholders expectations in order to protect, enhance and track reputation over time, as well as quantify the impact of reputation on key outcomes for the industry and its individual companies. At the core of the research is a proprietary model that isolates the key drivers that define the reputation of pharmaceutical companies. In mid-2013, APCO explored key stakeholders perceptions of the pharmaceutical industry in the Asia-Pacific region. The study is based on comprehensive quantitative research among health care opinion leaders, health care providers, policy leaders and payers. This groundbreaking study can be compared with studies in the United States and Europe along each of its key components: Key Drivers: The Reputation Model identifies the most important drivers of reputation for the pharmaceutical industry and its major companies. Overall Score: The Reputation Index captures the industry s reputation in a single metric derived from the relative impact each driver has on overall reputation and the perceived performance on each of those drivers. Strengths and Weaknesses: The Reputation Matrix isolates specific reputation strengths and, more importantly, the opportunities that can help improve the industry s reputation. To date, there has never been a study in the Asia-Pacific region of the pharmaceutical industry s reputation with this level of rigor and magnitude. The ROR Indicator, APCO s comprehensive reputation research offering, will go far in providing strategic support and guidance for pharmaceutical companies operating in the region. Amy Wendholt, managing director, APCO Worldwide in Hong Kong APCO s Return on Reputation Indicator provides companies with direction to support business strategies at the highest level all the way down to the tactics. To me, the most interesting information is learning what matters most to key stakeholders and then applying this knowledge to create strategic, targeted reputation programs. Through this process, APCO helped us enhance our organization s reputation on multiple levels. Phyllis Piano, former vice president, corporate communications and philanthropy at a major biotechnology company Outcomes: The ROR Indicator quantitatively measures the relationship between the reputation of the pharmaceutical industry and key outcomes, including consumer behavior, prescribing behavior, the litigation environment and financial value. 2
3 Return on Reputation Indicator Reputation Outcomes consumer behavior prescribing behavior litigation environment financial value What impact does reputation have on patients behavior? What impact does reputation have on prescribing behavior? What impact does reputation have on leading stakeholders to give the industry the benefit of the doubt when a crisis emerges? What impact does reputation have on shaping overall market/ shareholder value? Based on a sophisticated statistical analysis, the ROR Indicator reveals that, in the Asia-Pacific region, reputation can: Lead to more patients asking their doctors about a company s medicine: For every one-point increase on the Reputation Index, it is estimated that an additional 3.2 million patients will ask their doctors about a company s medicine. Lead to more patients recommending a company s medicine: For every one-point increase on the Reputation Index, it is estimated that an additional 5.5 million patients will recommend a company s medicine. Increase the number of prescriptions physicians write for a company s medicine: For every one-point increase on the Reputation Index, it is predicted that a physician will write in a month, on average, an additional two prescriptions for branded medications. Gain the benefit of the doubt when crises arise: The data suggests that a one-point increase in the Reputation Index could translate into more than 7 million additional people who are likely to support and defend the industry. Maximize shareholder value and increase market share: For the average pharmaceutical company, the data shows that a one-point increase in the Reputation Index can lead to an approximate 2 percent increase in product sales across the Asia-Pacific region. 3
4 Reputation Model The foundation of APCO s ROR Indicator is a robust model that measures the extent to which all stakeholders believe the industry, and the individual pharmaceutical companies, are meeting their unique and specific expectations. The model is based on more than a decade of extensive primary research in the sector and identifies 30 drivers that define the reputation of the pharmaceutical industry in the Asia-Pacific region. Correlations between the factors show there are six broad dimensions of reputation: Product Integrity, Stakeholder Engagement, Innovation, Access, Ethical Business Practices and Health Promotion. 4 UNIQUE CHARACTERISTICS OF THE ASIA-PACIFIC REPUTATION MODEL Product Integrity: Expectations for Product Integrity move beyond safety and efficacy to encompass the full product profile from ingredient sourcing to how it is manufactured and, ultimately, ensuring both product and process are available and in accordance with all laws and regulations in each market. Stakeholder Engagement: Building meaningful, cooperative relationships across key health care stakeholders, ranging from health care providers to policy leaders, to achieve public health priorities is integral to the reputation of companies operating in the Asia-Pacific region. Innovation: Expectations go beyond cutting-edge research and deep pipelines to also include aspects throughout the product lifecycle, such as discovery, post-market surveillance and value analytics. Additionally, expectations emerge that seek strengthening of Asia-Pacific-based R&D capabilities. Access: This factor encompasses a variety of attributes relating to fair and affordable pricing, transparency in health care costs and assistance in gaining access to medicines (free or discounted). A notable distinction from the U.S. model s focus on value, compared to an emphasis on affordability in Asia-Pacific. Ethical Business Practices: Relates to integrity in business operations and conduct, including support of the local economy through job creation. The Asia-Pacific expectations are explicitly inward facing, addressing only internal systems, whereas the U.S. model captures both internal and external factors (i.e., marketing to physicians and executive outreach). Health Promotion: In Asia-Pacific markets, supply integrity (keeping counterfeit medicines from entering the market) correlates with other Health Promotion factors more closely than others focused on product safety and efficacy. Comparative analysis is possible between APCO s ROR Indicator studies in Asia-Pacific, the United States and Europe. While the models reflect regional distinctions, there is consistency in the methodological approach, as well as discrete attributes, which allows for global insight. Additionally, year-to-year tracking of the validated models will reflect changing evaluations of the pharmaceutical industry in each region and stakeholder group.
5 Reputation Index The Reputation Index is a highly reliable measure of reputation for the Asia-Pacific pharmaceutical industry and its individual companies that ranges from 0 to 100. The index takes into account how the industry (or individual company) is rated along each of the 30 reputation drivers in the Reputation Model by each market and audience and the relative impact each factor plays in defining reputation. AUDIENCES Health Care Providers Opinion Leaders Policy Leaders & Payers JAPAN KOREA AUSTRALIA INDIA CHINA MARKETS Across the Asia-Pacific region, the industry receives a Reputation Index score of 65.0, well above the scale midpoint. Interestingly, compared to other regions, the Asia-Pacific Pharmaceutical Reputation Index is significantly higher than in the United States (61.3) and across Europe (60.7). The Reputation Index is computed separately for each market and stakeholder audience. By market, the industry s Reputation Index is the lowest in Japan at 59.6 and highest in China at 73.0 (a result of Chinese respondents tendency to offer higher ratings more generally). By audience, the industry s Reputation Index is the lowest among health care providers at 63.7 and highest among policy leaders and payers at 70.9, which is supported by ideal alignment with expectations. The value of the Reputation Index is that it provides a statistically valid measure of reputation overall and by each market and audience that can be tracked over time to determine the effectiveness of various initiatives and communication efforts. 5
6 Reputation Matrix The Reputation Matrix maps each of the 30 reputation drivers by their relative impact and performance on a macro level, representing the Asia-Pacific region as a whole, including all five markets and three stakeholder audiences. Ideal alignment with expectations is defined by high perceived performance on drivers that matter most, while weaker performance is seen on least impactful drivers. An efficient reputation management strategy aims to align drivers along this diagonal line in the matrix from bottom left to top right. Notably, the matrix for the pharmaceutical industry in the Asia-Pacific region reveals opportunities to enhance already strong alignment and lead to overall reputation improvement. On the whole, Product Integrity, Health Promotion and Innovation factors account for the largest proportion of reputation across the Asia-Pacific region. However, how well the industry performs on each of these discrete reputation drivers varies by market and stakeholder audience. The matrix provides a roadmap for prioritizing key industry initiatives and communication efforts, as well as a quantitative view on the extent to which these efforts actually move the needle on reputation. 6
7 Summary of Strengths and Opportunities to Improve Reputation Product Integrity: Threshold Expectations Encompassing The Full Product Profile The industry s value proposition is defined, in large part, by its commitment to Product Integrity expectations, despite anecdotal concerns about its commitment to Product Safety, Product Quality and good Manufacturing practices. Product Integrity, which also includes expectations related to Product Transparency, Compliance, Environmental Responsibility and Reliability, is a high-impact reputation driver and core reputation strength consistently across all stakeholder groups and markets. Bold Advancements and Sustainable Innovation: Core Assets to Protect and Leverage As pressure on the industry s development pipelines continues to grow, the need for strategic innovation investments is intensifying. Throughout the Asia-Pacific region, Innovation is identified as a core industry asset led by strengths in Bold Advancements, the what of innovation, and Sustainable Innovation, the how. Bold Advancements is the second leading driver of industry reputation and a core strength. Stakeholders expectations go beyond a desire for wholly new, life-saving medicines to also include personalized medicine a symbol of hope for future, high-value therapies. Sustainable Innovation is defined by a number of forward-looking expectations that seek to find efficient and sustainable ways to develop the medicines of tomorrow. In addition to maintaining a robust pipeline of potential new medicines and conducting cutting-edge and pioneering research, the industry s scientists are seen as essential to its Sustainable Innovation story. The industry receives particularly high marks for employing some of the world s leading scientists with a wide range of expertise and experience. Sustainable Innovation is viewed as a strength with relatively lower impact than Bold Advancements. Research Transparency and Research Partnerships: Heightened Expectations, Commitment Not Well-Known Research Transparency and Research Partnerships offer the greatest opportunities for reputation enhancement, as performance around the matrix midpoint suggests commitment is not well-known. Research Transparency, defined by ensuring research is open to review by the scientific community and other independent third parties and accurately and transparently reports results of research and clinical trials, is a critical area for the industry to address. In light of recent exponential growth in clinical trial studies across the region, as well as other high-profile transparency issues, expectations are heightened for responsible behavior. Research Partnerships, defined as participating in public-private partnerships to fund research and development of new treatments and actively supports and contributes to the development of [market s] domestic research capabilities, also presents an opportunity for the industry to focus its attention. In meeting growing demands to increase productivity, accelerate timelines and introduce efficiencies to research, pharmaceutical companies operating in the region are increasingly looking for new partners to help bring products to market. Meeting expectations for Research Partnerships may include public and private partnerships or support of regional R&D capabilities, such as financial investments, infrastructure development or other collaboration. Health Promotion: Expectation to Deliver Solutions to Public Health Challenges The global socio-economic impact of non-communicable diseases (NCDs) is staggering and a top concern in the Asia-Pacific region specifically. As such, Chronic Disease Management and Disease Awareness are top opportunities for the industry to shape its reputation: average performance and impact offers the chance to educate and lead. Opinion leaders, health care providers and policy leaders all expect the industry to play a prominent role in helping those in the region better address and manage NCDs. Stakeholders expect the industry to demonstrate how it leads the way in helping patients effectively manage chronic conditions and partnering with the public health community to share information/data to promote disease prevention, raise awareness of serious disease and emphasize long-term health outcomes. Additionally, there are heightened expectations for pharmaceutical 7
8 companies to establish long-term partnerships to fight diseases prevalent in each market. Drug Adherence is identified as a high-impact strength in three of the five markets in the study (China, Australia and Japan); though, it is viewed as a vulnerability in India and is less important in Korea. Stakeholder Engagement: Room for Improvement by Collaborating for Public Health Solutions Although the impact of Stakeholder Engagement in driving reputation tends to be modest, performance is often lacking. Misalignment is notable among opinion leaders and in India. Stakeholder Engagement is wide-ranging in scope, spanning from the industry s relationship with health care providers to its collaboration with public officials and other thought leaders. Provider Engagement is an impactful strength in most markets, although results suggest clarification is needed around its commitment to ethical marketing efforts toward physicians. However, among opinion leaders, Provider Engagement is a key vulnerability. As the industry cements its role as a trusted partner in helping solve critical public health challenges, it better meets the expectations of its stakeholders. Government Cooperation and Advocacy, on the other hand, are consistent vulnerabilities particularly among opinion leaders and health care providers, and in India, Australia and Korea. This is a possible consequence of efforts across these markets to streamline their regulatory structures in alignment with international standards of practice. The industry receives lower marks for preventing conflicts of interest with government officials and cooperating and sharing information with government payment agencies. Also, concerns about the industry s use of political influence threaten reputation, suggesting the industry s collaborative efforts with regulators and payers are not being recognized. The industry receives positive ratings for advocating for public policy that works toward the goal of improving public health, which supports the notion that the industry s cooperation and partnership with regulators and payers can help mitigate negative perceptions about its political influence while emphasizing its role as a public health advocate. Executive Engagement exerts less impact on overall reputation than other Stakeholder Engagement factors, with the notable exception of Japan, where it is a high-impact weakness. Executive Engagement is defined by having executives who are visibly involved and interacting with the community and who function as part of the solution to the industry s challenges by acting as thought leaders on key health care issues. Ethical Business Practices: Outshined by Other Industry Expectations Ethical Business Practices factors, defined by expectations related to Financial Strength, Employee Investment, Job Creation and Governance, comprise a lower proportion of overall reputation and are usually weaknesses, with some notable exceptions. Ethical Business Practices exert strong impact among policy leaders and payers, especially Employee Investment and Financial Strength, which are key assets, while Governance and Job Creation lag in performance. Access: Persistent Industry Weakness, Though Not Leading Impact Access and pricing issues are not limited to the developed world. Asia-Pacific markets, too, struggle with ongoing pricing pressures that are forcing cost containment measures to control the rising costs of pharmaceuticals. In the past few years, India, China, Japan, Korea and Australia have all instituted pricing reforms aimed at making medicines more affordable through strategies such as price cuts, co-payments, price and volume caps, as well as prescribing controls. Affordability and Pricing Transparency are perennial challenges facing the pharmaceutical industry and are among the industry s weakest performing drivers. Pricing Transparency defined by openness in drug pricing, describing how the cost of medicines is determined and demonstrating how medicines keep costs down is consistently a performance weakness though it tends to have a moderate impact on reputation. Affordability receives modestly better ratings, but is still below the performance midpoint. Patient Assistance and Philanthropy are among the least impactful reputation drivers, but performance is lacking. Offers free or discounted medicines to lower-income patients registers as the single lowest rated attribute in the study, with particularly low scores among health care providers. 8
9 Market-Level Summaries A closer look at the findings on a market-by-market level reveals interesting and important distinctions, as well as key commonalities. Alignment of drivers is quite strong in China, yielding a leading Reputation Index score, whereas in Australia reputation drivers are converged near the matrix center indicating a lack of clarity regarding the industry s value proposition. Performance ratings tend to be lower in Japan, coupled with some notable performance weaknesses, which lead to a lower overall Reputation Index score. Across markets examined in the Asia-Pacific region, Product Integrity and Innovation rise up as core assets of the industry, though alignment of discrete factors is unique in each market. Health Promotion also emerges as a strength; however, less so in India where, instead, Ethical Business Practices (especially Employee Investment) is identified as an asset. On the other hand, opportunities to improve perceptions of the industry are generally related to expectations for Stakeholder Engagement, Access and Ethical Business Practices. However, discrete opportunities vary considerably by market. Policy leaders and payers register the highest Reputation Index scores of the pharmaceutical industry in Australia, followed by opinion leaders and health care providers. Australia s matrix reveals opportunities to improve industry reputation, as a distinct cluster of drivers at the matrix center suggests a lack of clarity. As with other markets, Product Integrity is a threshold expectation and strength. Overall, Innovation is an asset despite a vulnerability in Research Partnerships and midline performance on Research Transparency. Health Promotion is also a reputation strength, led by Drug Adherence, although average or weak performance is seen in Chronic Disease Management and Disease Awareness. Policy leaders and payers register the highest Reputation Index scores of the pharmaceutical industry in China, followed by health care providers and opinion leaders. Product Integrity drivers are critical to defining the industry s reputation in China with notable assets related to Manufacturing, Product Safety and Compliance. Bold Advancements and Sustainable Innovation are perceived as core to the industry s value proposition across all audiences. However, stakeholders seek a clearer articulation of the industry s Research Transparency commitment. Health Promotion is also an opportunity for better alignment especially around Chronic Disease Management a high-impact driver where the industry receives weaker ratings. Notably, Chinese health care providers consider Health Promotion drivers particularly important in defining the industry s reputation. 9
10 Health care providers register the highest Reputation Index scores of the pharmaceutical industry in India, followed by opinion leaders, policy leaders and payers. Much like the rest of the Asia-Pacific markets surveyed, Product Integrity is a core asset, especially Manufacturing and Product Quality. Only in India does Stakeholder Engagement emerge as a high-impact vulnerability, with Advocacy and Government Cooperation drivers posing a particular challenge. On the other hand, Innovation exerts relatively less impact in shaping views of the industry in India notwithstanding key strengths in Bold Advancements and Sustainable Innovation. Also a notable performance strength is in Employee Investment, which is the single leading driver of reputation in India. Policy leaders and payers register the highest Reputation Index scores of the pharmaceutical industry in Korea, followed by health care providers and opinion leaders. Overall, alignment with expectations is strong in Korea. Product Integrity is a threshold expectation and strength. Innovation drivers are also leading impact expectations although opportunities for improvement exist related to midline performance on Research Transparency vulnerability on Research Partnerships. Commitment to Health Promotion can be clarified related to lukewarm performance on Chronic Disease Management and Disease Awareness. There is distinctively low impact related to Ethical Business Practices in Korea. Policy leaders and payers register the highest Reputation Index scores of the pharmaceutical industry in Japan, followed by opinion leaders and health care providers. In Japan, there is a tendency to offer lower performance ratings overall, which is reflected in a lower Reputation Index score than other markets, despite relatively strong alignment with expectations. Product Integrity drivers are core strengths in Japan. Health Promotion drivers are also key assets, especially Chronic Disease Management and Drug Adherence. Japan s Innovation strength is bolstered by Bold Advancements, but an opportunity for improvement exists in Comparative Effectiveness Research. Distinctive in Japan, Access tends to exert more impact than in other markets. 10
11 About the Study APCO Worldwide and its research consultancy APCO Insight developed the ROR Indicator, a robust measurement tool that takes an integrated approach to reputation management. The ROR Indicator study for the Asia-Pacific pharmaceutical industry is based on a quantitative survey that offers a holistic view of reputation across key markets and stakeholders. The complete findings for the pharmaceutical industry, as well as an interactive display of the data, can be viewed at Detailed, company-specific findings from the latest tracking phase of this groundbreaking research model are now available to member companies. In the most recent study, 12 of the top pharmaceutical companies were evaluated and, for many companies, comparative data to the United States is also available. Members receive a complete report of company-specific findings, including an in-depth view of the company s reputation ratings relative to the industry; a quantitative assessment of the key reputation strengths and opportunities for protecting and enhancing reputation across each market and among each audience; and the impact of reputation on key business outcomes. 11
12 To find out more about the ROR Indicator study or how your company can become a member and receive a custom report on company-specific findings, please contact: Amy Wendholt managing director, Hong Kong 1903 Cambridge House, TaiKoo Place 979 King s Road Hong Kong tel: awendholt@apcoworldwide.com Chrystine Zacherau director, health care research th Street, N.W. Suite 800 Washington, D.C tel: czacherau@apcoworldwide.com 2013 APCO Worldwide Inc. All rights reserved. Design: StudioAPCO
PAREXEL ACCESS MANAGED ACCESS PROGRAMS
PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationMay 9, Meeting Summary. Facilitating Antibacterial Drug Development
May 9, 2012 Meeting Summary Facilitating Antibacterial Drug Development Origins of the Current Public Health Crisis of Antibacterial Resistance Antibacterial drugs play a critical role in the ability to
More informationOptimizing the Impact of the Medical Affairs Function
Optimizing the Impact of the Medical Affairs Function Tim Dietlin, Vice President, Medical Affairs Practice Keith Morris, Practice Executive, Medical Affairs Practice Introduction The Medical Affairs function
More information2017 Global Pharmaceutical Scientific Process and Technology Outsourcing Customer Service Leadership Award
2017 Global Pharmaceutical Scientific Process and Technology Outsourcing Customer Service Leadership Award Contents Background and Company Performance... 3 Industry Challenges... 3 Quality of Customer
More informationMEDICAL AFFAIRS MEASUREMENT:
MEDICAL AFFAIRS MEASUREMENT: IDENTIFYING COMPLIANT KEY PERFORMANCE INDICATORS Gary Kaplan, M.A., Vice President, Medical Affairs Research, Clinical SCORE Once upon a time, it was easier to measure success.
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationJULY 2015 DECODING INTENDED NATIONALLY DETERMINED CONTRIBUTIONS (INDCS): A Guide for Understanding Country Commitments
JULY 2015 DECODING INTENDED NATIONALLY DETERMINED CONTRIBUTIONS (INDCS): A Guide for Understanding Country Commitments Learn what INDCs are, why they are important, what factors determine how robust they
More informationUsing Key Performing Indicators (KPIs) to measure, improve and communicate evidence of functional performance
Quantifying impact in Market Access / HEOR Using Key Performing Indicators (KPIs) to measure, improve and communicate evidence of functional performance www.kinapse.com Executive Summary With payers around
More informationMulti-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
WHITE PAPER Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes Author: SCOTT SCHLIEBNER Vice President, Rare Disease - Scientific Affairs
More informationStrategic Plan. Uniting to care & cure
2017-2020 Strategic Plan Uniting to care & cure Table of Contents Message from the President & CEO Page 2 Overview Page 3 Mission Page 4 Core Values Page 5 2017-2020 Objectives & Strategies Page 6 Mission
More informationTHE PRODUCT MINDSET 2013
CONSUMERS THE PRODUCT MINDSET 2013 MANUFACTURERS THE PRODUCT MINDSET 2013 The Product Mindset is an annual study created to better understand manufacturer and consumer concerns and priorities about the
More informationTHREE-YEAR STRATEGIC PLAN UPDATE v1
THREE-YEAR STRATEGIC PLAN UPDATE v1 FY2017-FY2019 OUR STRATEGY To develop future professionals through relevant and accessible credentialing programs 100% Member Market Penetration To deliver member value
More informationStrategic Plan. Uniting to care & cure
2017-2019 Strategic Plan Uniting to care & cure Table of Contents Message from the President & CEO Page 2 Overview Page 3 Mission Page 4 Core Values Page 5 2017-2019 Objectives & Strategies Page 6 Mission
More informationMarch 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette:
March 2, 2015 The Honorable Fred Upton Chairman Energy and Commerce Committee House of Representatives Washington, DC 20515 The Honorable Frank Pallone Ranking Member Energy and Commerce Committee House
More informationWhen customers are the cure
Life Sciences Of special interest to Chief financial officers Chief diversity officers Chief scientific officers Chief innovation officers Chief development officers Insights for 5executives When customers
More information2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award 2018 2018 NORTH AMERICAN REAL-WORLD EVIDENCE ENTERPRISE SOLUTIONS MARKET LEADERSHIP AWARD Contents Background and Company
More informationthe new era of responsibility CORPORATE RESPONSIBILITY REPORT
the new era of responsibility the pfizer commitment for today & tomorrow 11 THE NEW ERA OF RESPONSIBILITY Since our last corporate responsibility report in 2007, the world has changed dramatically. Although
More informationFinding the Balance between Clinical & Commercial Key Roles. Stewart Geary Chief Medical Officer, Senior Vice President, Eisai, Japan
IBC LIFE SCIENCES Part of: 4 TH ANNUAL Grand Copthorne Waterfront Hotel, Finding the Balance between Clinical & Commercial Key Roles Expert Faculty Include: Ajay Tiku Vice President Medical, Asia Pacific,
More informationDefining Strategic Metrics to Demonstrate Impact
The Value of Medical Affairs: Defining Strategic Metrics to Demonstrate Impact www.envisionpharmagroup.com The Value of Medical Affairs: Defining Strategic Metrics to Demonstrate Impact Objectives Establish
More informationPhysician Marketing & Outreach Growing Referring Physician Lifetime Value
Growing Referring Physician Lifetime Value Gelb, An Endeavor Management Company 1011 Highway 6 South P + 281.759.3600 Suite 120 F + 281.759.3607 Houston, Texas 77077 www.gelbconsulting.com Overview Today
More informationFACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET
FACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET A study undertaken by GfK Market Access on behalf of the European Biosimilars Group, a sector group of EGA, about the future sustainability
More informationThe Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview
The Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview Mission: The mission of The Endocrine Society is to advance excellence in endocrinology and promote
More informationEXPANDED ACCESS PROGRAMS
EXPANDED ACCESS PROGRAMS PRACTICAL OPERATIONAL CONSIDERATIONS While patient demand for expanded access is growing, a clear consensus has yet to emerge on the best way to address this demand. Debate continues
More informationWHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific
WHITE PAPER establishing a regulatory Drug Development Strategy for Asia Pacific ppdi.com July 2012 EXECUTIVE SUMMARY As the economic power of China and other Asian countries grows, many biopharmaceutical
More informationBEST PRACTICES IN Talent Management Article Title Format
SCHOONOVER ASSOCIATES WHITE PAPER BEST PRACTICES IN Talent Management Article Title Format SCHOONOVER ASSOCIATES, LLC. 2015 Dr. Stephen C. Schoonover President, Schoonover Associates, LLC Contents Executive
More informationBenefits of Membership
Benefits of Membership Leadership Collaboration Innovation Grocery Manufacturers Association Representing the Makers of the World s Favorite Food, Beverage and Consumer Products The consumer packaged goods
More informationStrategic Plan FY14 - FY18
Strategic Plan FY14 - FY18 Wellesley Institute 5.0 Transforming and sustaining healthy communities by reducing health inequities within a population health framework April, 2013 The Wellesley Institute
More informationZS Medical Affairs Outlook Report Analysis of Field Medical Growth and Industry Trends
ZS Medical Affairs Outlook Report 2017 Analysis of Field Medical Growth and Industry Trends ZS Medical Affairs Outlook Report 2017 Analysis of Field Medical Growth and Industry Trends Forward by Sarah
More informationA Framework for Audit Quality
Ernst & Young Global Limited Becket House 1 Lambeth Palace Road London SE1 7EU Tel: +44 [0]20 7980 0000 Fax: +44 [0]20 7980 0275 www.ey.com Mr. James Gunn Technical Director International Auditing and
More informationTaking ERM to a. 6 GRC Today / October 2015
GLOBAL SCALE 6 GRC Today / October 2015 Global Scale lobal events highlighted by G business scandals, failures, information theft, and natural disasters have shone the spotlight yet again on risk management
More informationPowering the Life Sciences Commercial Engine with Market Access Insights
Powering the Life Sciences Commercial Engine with Market Access Insights April 2017 CONTENTS 1. Introduction 3 2. The Race for Market Access Insights has Begun 4 3. Life Sciences is Not Yet Firing on All
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationImprove your probability. of success
Improve your probability of success FROM PIPELINE TO PORTFOLIO TO POPULATION HEALTH TM Creating a healthier world will require the industry s best thinking and resources. It will also demand working together
More informationAn integrated model approach to improve the management of marketed products
Insight brief Regulatory and safety integration An integrated model approach to improve the management of marketed products Leo Dodds, Principal, Quintiles Advisory Services John Rogers, Engagement Leader,
More informationAligning internal teams to secure buy-in from external stakeholders: a critical part of launch strategy
October 2015 Aligning internal teams to secure buy-in from external stakeholders: a critical part of launch strategy The commercial success of a new pharmaceutical product depends on the buy-in of disparate
More information3. Why is California taking the lead in this area? 4. Is this just a California initiative? Aren t ACOs important throughout the country?
Integrated Healthcare Association (IHA) and Pacific Business Group on Health (PBGH) Partner on Commercial ACO Measurement & Benchmarking Initiative FREQUENTLY ASKED QUESTIONS 1. What is the Commercial
More informationNATIONAL BOARD OF MEDICAL EXAMINERS SENIOR VICE PRESIDENT, ASSESSMENT PROGRAMS
NATIONAL BOARD OF MEDICAL EXAMINERS SENIOR VICE PRESIDENT, ASSESSMENT PROGRAMS The Search The (NBME) seeks an experienced, collaborative, and entrepreneurial leader for the position of Senior Vice President
More informationEnterprise Performance Management in the Pharmaceutical Industry. kpmg.co.uk
Enterprise Performance Management in the Pharmaceutical Industry kpmg.co.uk Are your performance management processes, metrics and tools prepared for tomorrow s strategic challenges in pharmaceuticals?
More informationThe DAC s main findings and recommendations. Extract from: OECD Development Co-operation Peer Reviews
The DAC s main findings and recommendations Extract from: OECD Development Co-operation Peer Reviews Australia 2018 2 DCD/DAC/AR(2018)2/23/PART1/FINAL Australia has made progress towards influencing globally
More informationFactors Supporting a Sustainable European Biosimilar Medicines Market PROJECT SUMMARY FOR EXTERNAL COMMUNICATION
Market Access Factors Supporting a Sustainable European Biosimilar Medicines Market PROJECT SUMMARY FOR EXTERNAL COMMUNICATION A study undertaken by GfK Market Access on behalf of the European Biosimilars
More informationWHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs
Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs 1 Executive Summary In today s complex healthcare landscape, the success or failure of a new therapeutic intervention depends
More informationPutting a number on your brand health is just the start.
Putting a number on your brand health is just the start. Being able to quantify the health of your brand is invaluable. But at Ketchum, we believe the real ROI comes from knowing how to improve that number.
More informationUPS Healthcare Supply Chain Vital Signs
UPS Study Executive September 2017 START 2017 UPS Survey 2017 United Parcel Service of America, Inc. 1 An industry growing more complex: managing competition, compliance and costs Pharmacies are grappling
More informationDoctor/pharma relationships: the latest research
Creating connections, improving healthcare Doctor/pharma relationships: the latest research medicine media metamorphosis The huge shift in knowledge sharing has affected how doctors interact with the healthcare
More informationAdvisory & Client Services
Advisory & Client Services BlackRock was founded by eight entrepreneurs who wanted to start a very different company. One that combined the best of a financial leader and a technology pioneer. And one
More informationsocial, and population-based research conducted and supported by the National Institutes of Health (NIH). The
Statement by the Ad Hoc Group for Medical Research on FY 2015 Appropriations for the National Institutes of Health Submitted for the record on March 28, 2014, to the Subcommittee on Labor, Health and Human
More informationFrom discussion to implementation: How to negotiate and implement a risk-sharing agreement
July 2017 From discussion to implementation: How to negotiate and implement a risk-sharing agreement At the table with payers and manufacturers Background The groundswell of interest in value-based drug
More informationInformation governance for the real world
Information governance for the real world 1 2 Information governance is the activities and technologies that organizations employ to maximize the value of their information while minimizing associated
More informationCORPORATE SUSTAINABILITY. Driving stewardship from strategy to implementation
CORPORATE SUSTAINABILITY Driving stewardship from strategy to implementation OUR SERVICES Sustainability objectives differ for each client depending on materiality, stakeholder objectives and business
More informationCORPORATE SUSTAINABILITY
CORPORATE SUSTAINABILITY STEWARDSHIP STRATEGY & IMPLEMENTATION WWW.RAMBOLL.COM OUR SERVICES Sustainability objectives differ for each client depending on materiality, stakeholder objectives and business
More informationId. 3. Id. Docket # USTR Edward Gresser Chair of the Trade Policy Staff Committee Office of the United States Trade Representative
Docket # USTR-2018-0034 Edward Gresser Chair of the Trade Policy Staff Committee Office of the United States Trade Representative The Biotechnology Innovation Organization (BIO) appreciates the opportunity
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More informationHR Connect Asia Pacific
Employee Engagement Trends in Hong Kong and its Impact on Employers By Andy Leung, Senior Consultant, Aon Hewitt Hong Kong The economic recession that started in 2008 dramatically changed the landscape
More informationDeveloping Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
More informationSTRATEGIC PLAN. Effective July 2016
STRATEGIC PLAN Effective July 2016 I. STRATEGIC PLAN MISSION, VISION, VALUES MISSION: Strengthen demand for U.S. Potatoes VISION: Create positive change in the industry through innovative and inspiring
More informationRole Type Pay Band Location Duration Reports to: East Asia Flexible (Singapore Preferred)
Role Title Regional Senior Internal Communications Manager Role Information Role Type Pay Band Location Duration Reports to: Communications 7/F East Asia Flexible (Singapore Preferred) Permanent Regional
More informationOptimised for Growth:
The Fifth Annual Change in the (Supply) Chain Survey REGIONAL SUMMARY: ASIA PACIFIC Optimised for Growth: High-Tech Executives Adapt to Meet Global Demands INTRODUCTION Optimised for Growth: High-Tech
More informationThe State of Sustainable Business Results of the 10 th Annual Survey of Sustainable Business Leaders 2018
The State of Sustainable Business 2018 Results of the 10 th Annual Survey of Sustainable Business Leaders 2018 Table of Contents Introduction + Key Findings 3 Sustainability Priorities 9 Sustainability
More informationOptimized for Growth:
The Fifth Annual Change in the (Supply) Chain Survey REGIONAL SUMMARY: LATIN AMERICA Optimized for Growth: High-Tech Executives Adapt to Meet Global Demands INTRODUCTION Optimized for Growth: High-Tech
More informationBenchmarking the Pharma Industry s HEOR Functions
EW PR EV I Benchmarking the Pharma Industry s HEOR Functions Info@ISRreports.com 2013 Industry Standard Research www.isrreports.com Report Overview This report provides pharmaceutical and biotech organizations
More informationThe Future of Pharmaceuticals for Human Use in Europe Cefic Input to the Consultation Process: Deadline for Submission 12/10/2007 Date: 10/10/07
The Future of Pharmaceuticals for Human Use in Europe Cefic Input to the Consultation Process: Deadline for Submission 12/10/2007 Date: 10/10/07 CEFIC is the organisation that represents national federations,
More informationOur Story. Contents. 550 Clients. 62 Countries Served. 275 Stars Rated Universities. 4,300 Universities Analysed For QSWUR
Guide to Services Advanced and innovative sectoral intelligence, and consulting and analytics solutions to help you harness your potential, facilitate your growth, and enhance your performance Our Story
More informationCBRE INDUSTRIAL & LOGISTICS ADVISORY & TRANSACTION SERVICES
CBRE INDUSTRIAL & LOGISTICS ADVISORY & TRANSACTION SERVICES CBRE Industrial & Logistics Services represents the largest industrial services platform in the world, offering an integrated suite of advisory,
More informationRisk Advisory Services Developing your organisation s governance for competitive advantage
Advisory Services Developing your organisation s governance for competitive advantage The Deloitte Advisory Platform of Services can help you to govern your strategic plan to guide your operations measure
More informationChange Healthcare Performance Analytics. Identify Opportunities for Financial, Clinical, and Operational Improvement
Change Healthcare Performance Analytics Identify Opportunities for Financial, Clinical, and Operational Improvement Inspiring a Better Healthcare System For years, healthcare organizations have focused
More informationThe EFQM 2013 Model Changes. Implications for Organizations
1-June-13 The EFQM 2013 Model Changes Implications for Organizations by Sunil Thawani EFQM reviews the EFQM Excellence model every three years to ensure it continues to reflect reality and relevance to
More informationEnterprise Value Management
Delivering on the Promise of "Value-Add" Enterprise Value Management Client Challenges How can I reduce the risk of my investment strategies failing? It s easy to say what we have to spend more money on.
More informationLOGISTICS PERFORMANCE INDEX 2010: THE ASIA-PACIFIC REGION
LOGISTICS PERFORMANCE INDEX 2010: THE ASIA-PACIFIC REGION Findings based on the World Bank Report Connecting to Compete 2010: Trade Logistics in the Global Economy Credits for Photographs on the Cover
More informationFinancial Advisory. Valuation Services. Life Science Industry
Financial Advisory Services Life Science Industry Fact sheet: Life Science Industry Services Many life sciences companies struggle with nurturing the promise of innovative discoveries in a volatile market
More informationDriving healthy growth
Health Care Of special interest to Boards of directors The C-suite Health care executives 5Insights for executives Driving healthy growth The value of a proactive stance to compliance Organizations throughout
More informationAssociate Group Medical Director - MD
Date: 06/11/18 Associate Group Medical Director - MD Job ID: 201805-106259 Job Function Clinical Development Location United States of America - California South San Francisco Schedule Full time Job type
More informationThe Ohio State University Human Resources Strategic Plan
Human Resources 2018-2023 Strategic Plan Finalized: May 16, 2018 Delivering HR Excellence. Inspiring People. Leading Change. HR.OSU.EDU 1590 N. High Street, Suite 300 Columbus, OH 43201 614-292-1050 Table
More informationThe State of Sustainable Business Results of the 8 th Annual Survey of Sustainable Business Leaders October 2016
The State of Sustainable Business 2016 Results of the 8 th Annual Survey of Sustainable Business Leaders October 2016 Contents About the Research 3 Sample and Methodology 5 Key Findings 7 Overall Priorities
More informationAnnie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015
Annie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015 On behalf of Parent Project Muscular Dystrophy (PPMD), we are most grateful
More informationPerformance Management in Higher Education
Performance Management in Higher Education Advisory Services and Software Solutions That Enable Colleges and Universities to Succeed in a Changing Environment Given the number and magnitude of pressures
More informationOperational Excellence in Healthcare. Creating a Culture of High Reliability: Management System Fundamentals
Operational Excellence in Healthcare Creating a Culture of High Reliability: Management System Fundamentals OUR VIEW Set, Met, Reinforced The Key to Experience Management We believe that your brand, operations
More informationAshfield Commercial. Commercial & Medical Services. INSIGHT & PERFORMANCE Business Edge InforMed Insight Pharma Marketing Academy
COMMERCIAL Ashfield In2Focus Pharmexx Ashfield Commercial Ashfield Healthcare Ireland Ashfield KK Expansis Ashfield MCG CLINICAL Ashfield In2Focus Pharmexx Ashfield Healthcare Ashfield Healthcare Ireland
More informationBIOTECH, MED DEVICE & PHARMA
WHITEPAPER Key Account Management Strategies for BIOTECH, MED DEVICE & PHARMA INTRODUCTION Changes in the healthcare landscape have led to changes in customers. In an environment where healthcare providers
More information2013/2014 Report
2013/2014 Staying@Work Report U.S. Executive Summary Introduction U.S. organizations have long looked to health and productivity programs as one way to keep workers healthier and stem the tide of higher
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationBest Practices to Prevent Supply Chain Quality Issues
W H I T E P A P E R Best Practices to Prevent Supply Chain Quality Issues INTRODUCTION A high-quality, vetted supply chain affects the efficiency and sustainability of health services at all levels, be
More informationActive Essex Risk Management Strategy
Active Essex Risk Management Strategy 2017-2021 November 2017 Contents 1. Policy Statement 2. Statement of Commitment 3. Risk Management Framework 4. Risk Appetite 5. Risk Maturity 6. Risk Management Levels
More informationState of Sustainable Business Survey 2014
State of Sustainable Business Survey 2014 October 2014 The sixth annual study explores the views of corporate sustainability practitioners About BSR BSR is a global nonprofit organization that works with
More informationGLOBAL TRENDS SURVEY REPORT
GLOBAL TRENDS SURVEY REPORT + OVERVIEW Clinical trials have become increasingly global in scope. Some countries require testing of drugs in a country before they can be approved for sale in that country.
More informationASSISTANCE AND ASSESSMENT:
ASSISTANCE AND ASSESSMENT: HELPING PHARMA MEASURE AND MAXIMIZE MEDICAL AFFAIRS PERFORMANCE Gary Kaplan, M.A., Vice President, Medical Affairs Research, ClinicalSCORE Effective Medical Affairs More Critical
More informationSatyam Among First Indian Companies to Publish IFRS-Audited Financials
Satyam Among First Indian Companies to Publish IFRS-Audited Financials New reporting approach more visible to marketplace, investors HYDERABAD, India, April. 21, 2008 Satyam Computer Services Ltd. (NYSE:SAY),
More informationPharma Medical Affairs 2020 and beyond. Matthias Evers Edd Fleming Arnab Ghatak Jan Hartmann Arif Nathoo Ron Piervincenzi Lawrence Wai Ann Westra
Pharma Medical Affairs 2020 and beyond Matthias Evers Edd Fleming Arnab Ghatak Jan Hartmann Arif Nathoo Ron Piervincenzi Lawrence Wai Ann Westra A rapidly changing world for Medical Affairs Pharma s Medical
More informationQUICK FACTS. Delivering a Managed Services Solution to Satisfy Exponential Business Growth TEKSYSTEMS GLOBAL SERVICES CUSTOMER SUCCESS STORIES
[ Financial Services, Application Management Outsourcing ] TEKSYSTEMS GLOBAL SERVICES CUSTOMER SUCCESS STORIES Client Profile Industry: Financial Services Revenue: Approximately $30 billion annually (parent
More informationConstructing Healthy China: Sharing, Innovation & Sustainable Development
Constructing Healthy China: Sharing, Innovation & Sustainable Development 3 / 1/2017 Table of Contents Chapter One: Healthy China 2030...3 1. Healthy China 2030 is the first long-term national strategy
More informationConference KeyNotes key issues benchmarks action plans
Conference KeyNotes key issues benchmarks action plans Human Capital Metrics Conference: Predicting Success through People As a community of business leaders, The Conference Board convenes senior executives
More informationInvesting in Rare Disease Patient Advocacy Groups
Investing in Rare Disease Patient Advocacy Groups Written by: Pooja Doshi, Engagement Manager, ClearView Healthcare Partners Chris Von Seggern, Partner, ClearView Healthcare Partners Patient Advocacy Groups
More informationInternational Conference and Exhibition on Drug Processing, Labeling & Packaging
(Theme: Encounter Innovations in Pharma Labeling, Packaging and Innovative in Drug Processing) About the Conference: Drug Packaging-2015 welcomes attendees, presenters, and exhibitors from all over the
More information2013 Southwind Institute
2013 Southwind Institute Anthony M. D Eredita Executive Vice President Southwind, A Division of The Advisory Board 2 The M&A Wave is On-going: Hospital and Physician Scale thought to be an answer but may
More informationEstablishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
More informationPEFC Strategy Summary
PEFC Strategy 2013-2016 Summary Becoming the Partner of Choice 1 of 5 INTRODUCTION PEFC has a strong role in promoting best practices in the forest, with specific consideration to the role of small-, family-
More informationShifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go
Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Shifting Pharma Sales Models to Focus on Providing
More informationLife Sciences Compliance in Asia
Life Sciences Compliance in Asia How the Evolution of Asia s Compliance Landscape is Driving Uncertainty 2017 kpmg.com.sg The Evolution of Asia s Compliance Landscape is Driving Uncertainty For many Life
More informationTransparency as a Good Business Practice
Transparency as a Good Business Practice Exploring How Transparency Can Drive Best Practices in Business Strategy August 2017 Polaris Management Partners Agenda Compliance Trends 2017-2018 Deriving Strategic
More information